Table 2.
Baseline characteristics of the study subjects.
| All | CI | No CI | p | |
|---|---|---|---|---|
| n = 84 | n = 27 | n = 57 | ||
| Age, yr | 71.6 ± 8.7 | 74.1 ± 6.6 | 70.4 ± 9.4 | 0.04∗ |
| Male, % | 61.9 | 66.7 | 59.7 | 0.53 |
| Hypertension, % | 73.8 | 77.8 | 71.9 | 0.57 |
| Dyslipidemia (LDL ≧ 140 mg/dL/statin user), % | 45.2 | 63 | 36.8 | 0.04∗ |
| LDL ≧ 140 mg/dL, % | 10.7 | 14.8 | 8.8 | 0.46 |
| Diabetes, % | 42.9 | 55.6 | 36.8 | 0.11 |
| Smoking, % | 59.5 | 63 | 57.9 | 0.66 |
| Family history, % | 10.7 | 11.1 | 10.5 | 0.94 |
| Prior stroke, % | 14.3 | 18.5 | 12.3 | 0.45 |
| Prior MI, % | 26.2 | 29.6 | 24.6 | 0.62 |
| MI within 7 days prior, % | 6.0 | 11.1 | 3.5 | 0.17 |
| EF < 40, % | 13.1 | 22.2 | 8.8 | 0.09 |
| PVD, % | 28.6 | 40.7 | 22.8 | 0.09 |
| CAD, % | 60.7 | 77.8 | 52.6 | 0.03∗ |
| Cre > 1.5 mg/dL, % | 14.3 | 14.8 | 14.4 | 0.92 |
| Severe aortic stenosis, % | 11.9 | 3.7 | 15.8 | 0.11 |
| AF, % | 10.7 | 14.8 | 8.8 | 0.40 |
| Preprocedural medication | ||||
| Statin, % | 38.1 | 51.9 | 31.6 | 0.09 |
| ACE-I/ARB, % | 47.6 | 51.9 | 45.6 | 0.59 |
| Beta blocker, % | 29.8 | 37 | 26.3 | 0.32 |
| CCB, % | 51.2 | 55.6 | 49.1 | 0.58 |
| Antiplatelet, % | 53.6 | 74 | 43.9 | 0.01∗ |
| Anticoagulation, % | 13.1 | 18.5 | 10.5 | 0.31 |
∗Included in multivariate analysis.
LDL: low-density lipoprotein; MI: myocardial infarction; PVD: peripheral vascular disease; CAD: coronary artery disease; AF: atrial fibrillation; ACE-I: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blocker.